714 related articles for article (PubMed ID: 30770030)
1. Insulin resistance and insulin hypersecretion in the metabolic syndrome and type 2 diabetes: Time for a conceptual framework shift.
Nolan CJ; Prentki M
Diab Vasc Dis Res; 2019 Mar; 16(2):118-127. PubMed ID: 30770030
[TBL] [Abstract][Full Text] [Related]
2. Insulin resistance and reduced metabolic flexibility: cause or consequence of NAFLD?
Gastaldelli A
Clin Sci (Lond); 2017 Nov; 131(22):2701-2704. PubMed ID: 29109303
[TBL] [Abstract][Full Text] [Related]
3. Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges.
Jeanes YM; Reeves S
Nutr Res Rev; 2017 Jun; 30(1):97-105. PubMed ID: 28222828
[TBL] [Abstract][Full Text] [Related]
4. Adverse metabolic phenotype of adolescent girls with non-alcoholic fatty liver disease plus polycystic ovary syndrome compared with other girls and boys.
Ayonrinde OT; Adams LA; Doherty DA; Mori TA; Beilin LJ; Oddy WH; Hickey M; Sloboda DM; Olynyk JK; Hart R
J Gastroenterol Hepatol; 2016 May; 31(5):980-7. PubMed ID: 26589977
[TBL] [Abstract][Full Text] [Related]
5. Associations of vitamin D with insulin resistance, obesity, type 2 diabetes, and metabolic syndrome.
Wimalawansa SJ
J Steroid Biochem Mol Biol; 2018 Jan; 175():177-189. PubMed ID: 27662816
[TBL] [Abstract][Full Text] [Related]
6. Nonalcoholic fatty liver disease in children and adolescents - Relationship with Polycystic Ovary Syndrome.
Abruzzese GA; Motta AB
Curr Pharm Des; 2015; 21(35):5144-50. PubMed ID: 26412465
[TBL] [Abstract][Full Text] [Related]
7. Swimming, but not vitamin E, ameliorates prothrombotic state and hypofibrinolysis in a rat model of nonalcoholic fatty liver disease.
Sakr HF; Abbas AM; Haidara MA
J Basic Clin Physiol Pharmacol; 2018 Jan; 29(1):61-71. PubMed ID: 29161233
[TBL] [Abstract][Full Text] [Related]
8. Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound.
Petrović G; Bjelaković G; Benedeto-Stojanov D; Nagorni A; Brzački V; Marković-Živković B
Vojnosanit Pregl; 2016 Oct; 73(10):910-20. PubMed ID: 29327896
[TBL] [Abstract][Full Text] [Related]
9. Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease.
Baranova A; Tran TP; Birerdinc A; Younossi ZM
Aliment Pharmacol Ther; 2011 Apr; 33(7):801-14. PubMed ID: 21251033
[TBL] [Abstract][Full Text] [Related]
10. Metabolically healthy and unhealthy obese--the 2013 Stock Conference report.
Samocha-Bonet D; Dixit VD; Kahn CR; Leibel RL; Lin X; Nieuwdorp M; Pietiläinen KH; Rabasa-Lhoret R; Roden M; Scherer PE; Klein S; Ravussin E
Obes Rev; 2014 Sep; 15(9):697-708. PubMed ID: 25059108
[TBL] [Abstract][Full Text] [Related]
11. Ultrasonographic and laboratory markers of metabolic and cardiovascular disease risk in obese women with polycystic ovary syndrome.
Zueff LF; Martins WP; Vieira CS; Ferriani RA
Ultrasound Obstet Gynecol; 2012 Mar; 39(3):341-7. PubMed ID: 21898634
[TBL] [Abstract][Full Text] [Related]
12. Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome.
Kelley CE; Brown AJ; Diehl AM; Setji TL
World J Gastroenterol; 2014 Oct; 20(39):14172-84. PubMed ID: 25339805
[TBL] [Abstract][Full Text] [Related]
13. Cholesterol efflux capacity is impaired in subjects with an elevated Fatty Liver Index, a proxy of non-alcoholic fatty liver disease.
van den Berg EH; Gruppen EG; Ebtehaj S; Bakker SJL; Tietge UJF; Dullaart RPF
Atherosclerosis; 2018 Oct; 277():21-27. PubMed ID: 30170220
[TBL] [Abstract][Full Text] [Related]
14. High-sensitivity C-reactive protein (hs-CRP) levels and its relationship with components of polycystic ovary syndrome in Indian adolescent women with polycystic ovary syndrome (PCOS).
Ganie MA; Hassan S; Nisar S; Shamas N; Rashid A; Ahmed I; Douhat S; Mudassar S; Jan VM; Rashid F
Gynecol Endocrinol; 2014 Nov; 30(11):781-4. PubMed ID: 25137507
[TBL] [Abstract][Full Text] [Related]
15. An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome.
Brzozowska MM; Ostapowicz G; Weltman MD
J Gastroenterol Hepatol; 2009 Feb; 24(2):243-7. PubMed ID: 19215335
[TBL] [Abstract][Full Text] [Related]
16. Hepatic insulin resistance in NAFLD: relationship with markers of atherosclerosis and metabolic syndrome components.
Privitera G; Spadaro L; Alagona C; Calanna S; Piro S; Rabuazzo AM; Purrello F
Acta Diabetol; 2016 Jun; 53(3):449-59. PubMed ID: 26496770
[TBL] [Abstract][Full Text] [Related]
17. Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS.
Petta S; Ciresi A; Bianco J; Geraci V; Boemi R; Galvano L; Magliozzo F; Merlino G; Craxì A; Giordano C
PLoS One; 2017; 12(11):e0186136. PubMed ID: 29161258
[TBL] [Abstract][Full Text] [Related]
18. Fetuin-B links nonalcoholic fatty liver disease to type 2 diabetes via inducing insulin resistance: Association and path analyses.
Li Z; Lin M; Liu C; Wang D; Shi X; Chen Z; Liu Y; Yang S; Li X
Cytokine; 2018 Aug; 108():145-150. PubMed ID: 29609136
[TBL] [Abstract][Full Text] [Related]
19. Nonalcoholic fatty liver disease and polycystic ovary syndrome.
Vassilatou E
World J Gastroenterol; 2014 Jul; 20(26):8351-63. PubMed ID: 25024594
[TBL] [Abstract][Full Text] [Related]
20. Metabolic Syndrome During Menopause.
Mumusoglu S; Yildiz BO
Curr Vasc Pharmacol; 2019; 17(6):595-603. PubMed ID: 30179134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
